Literature DB >> 19050689

Molecular markers in prostate cancer. Part II: potential roles in management.

Sachin Agrawal1, Krishnaji P Patil, William D Dunsmuir.   

Abstract

Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as potential therapeutic targets using gene therapy and immunomodulation. Additionally, markers identified in early PCa and precursor lesions may offer novel targets for chemoprevention and vaccine development. This review summarizes the current advances regarding the roles of these markers in the management of PCa.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19050689      PMCID： PMC3735215          DOI： 10.1038/aja.2008.23

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


  48 in total

Review 1.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 2.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

3.  Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Authors:  Deborah L Marrocco; Wayne D Tilley; Tina Bianco-Miotto; Andreas Evdokiou; Howard I Scher; Richard A Rifkind; Paul A Marks; Victoria M Richon; Lisa M Butler
Journal:  Mol Cancer Ther       Date:  2007-01-11       Impact factor: 6.261

Review 4.  Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.

Authors:  Michael A Carducci; Antonio Jimeno
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

5.  In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

Authors:  J R Herman; H L Adler; E Aguilar-Cordova; A Rojas-Martinez; S Woo; T L Timme; T M Wheeler; T C Thompson; P T Scardino
Journal:  Hum Gene Ther       Date:  1999-05-01       Impact factor: 5.695

6.  Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.

Authors:  P De Miguel; R Bethencourt; A Ruiz; B Fraile; R Paniagua
Journal:  Cytokine       Date:  1999-09       Impact factor: 3.861

7.  Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.

Authors:  Yasutomo Nasu; Takashi Saika; Shin Ebara; Nobuyuki Kusaka; Haruki Kaku; Fernando Abarzua; Daisuke Manabe; Timothy C Thompson; Hiromi Kumon
Journal:  Mol Ther       Date:  2007-02-27       Impact factor: 11.454

8.  Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity.

Authors:  Kai S Lipinski; Steven Pelech; Andrew Mountain; Alistair S Irvine; Robert Kraaij; Chris H Bangma; Kingston H G Mills; Stephen M Todryk
Journal:  Cancer Immunol Immunother       Date:  2005-06-17       Impact factor: 6.968

Review 9.  Molecular therapy in urologic oncology.

Authors:  Michael Froehner; Oliver W Hakenberg; Manfred P Wirth
Journal:  Urol Int       Date:  2007       Impact factor: 2.089

Review 10.  Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.

Authors:  Norman Chan; Michael Milosevic; Robert G Bristow
Journal:  Future Oncol       Date:  2007-06       Impact factor: 3.404
View more
  2 in total

Review 1.  Positron emission tomography imaging of prostate cancer.

Authors:  Hao Hong; Yin Zhang; Jiangtao Sun; Weibo Cai
Journal:  Amino Acids       Date:  2009-11-28       Impact factor: 3.520

2.  An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.

Authors:  Hai-Liang Zhang; Xiao-Jian Qin; Da-Long Cao; Yao Zhu; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2013-02-04       Impact factor: 3.285
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.